TRCT
EWTX icon

Tower Research Capital (TRC)’s Edgewise Therapeutics EWTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
2,812
-2,661
-49% -$91.7K ﹤0.01% 2087
2026
Q1 		$172K Buy
5,473
+3,860
+239% +$111K ﹤0.01% 1733
2025
Q4 		$40K Sell
1,613
-26
-2% -$522 ﹤0.01% 2598
2025
Q3 		$26.6K Sell
1,639
-7,509
-82% -$107K ﹤0.01% 3053
2025
Q2 		$120K Buy
9,148
+1,188
+15% +$17.1K ﹤0.01% 2232
2025
Q1 		$175K Buy
7,960
+4,284
+117% +$112K 0.01% 1441
2024
Q4 		$98.1K Buy
3,676
+3,369
+1,097% +$107K ﹤0.01% 2149
2024
Q3 		$8.19K Sell
307
-5,283
-95% -$105K ﹤0.01% 3977
2024
Q2 		$101K Buy
5,590
+5,120
+1,089% +$89.3K ﹤0.01% 2577
2024
Q1 		$8.57K Sell
470
-17,767
-97% -$282K ﹤0.01% 3997
2023
Q4 		$200K Buy
18,237
+12,181
+201% +$85.5K ﹤0.01% 2101
2023
Q3 		$34.7K Buy
6,056
+4,833
+395% +$32.9K ﹤0.01% 2893
2023
Q2 		$9.48K Sell
1,223
-15,177
-93% -$128K ﹤0.01% 4275
2023
Q1 		$109K Buy
16,400
+9,796
+148% +$90.8K ﹤0.01% 1792
2022
Q4 		$59K Buy
6,604
+2,829
+75% +$26.5K ﹤0.01% 2222
2022
Q3 		$37K Buy
3,775
+2,555
+209% +$25.8K ﹤0.01% 3423
2022
Q2 		$10K Sell
1,220
-922
-43% -$6.97K ﹤0.01% 4442
2022
Q1 		$21K Buy
2,142
+861
+67% +$11.1K ﹤0.01% 3481
2021
Q4 		$20K Buy
1,281
+810
+172% +$14.6K ﹤0.01% 3661
2021
Q3 		$8K Buy
471
+177
+60% +$3.2K ﹤0.01% 4533
2021
Q2 		$6K Buy
+294
New +$8.04K ﹤0.01% 4623

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s EWTX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Edgewise Therapeutics (EWTX) stake by 49% in Q2 2026, selling an estimated $91.7K and leaving 2,812 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Tower Research Capital (TRC) first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $200K in Q4 2023. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,812 shares of Edgewise Therapeutics worth $114K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,661 Edgewise Therapeutics shares in Q2 2026, an estimated $91.7K.
  • Edgewise Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2087 holding.
  • Tower Research Capital (TRC) first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Edgewise Therapeutics position peaked at $200K in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.